Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,978,436
  • Shares Outstanding, K 37,570
  • Annual Sales, $ 0 K
  • Annual Income, $ -102,900 K
  • 60-Month Beta 2.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 21.80
Trade AXSM with:

Options Overview

Details
  • Implied Volatility 87.68%
  • Historical Volatility 50.95%
  • IV Percentile 95%
  • IV Rank 76.96%
  • IV High 98.34% on 04/23/21
  • IV Low 52.08% on 01/20/21
  • Put/Call Vol Ratio 0.15
  • Today's Volume 2,785
  • Volume Avg (30-Day) 1,560
  • Put/Call OI Ratio 1.78
  • Today's Open Interest 42,000
  • Open Int (30-Day) 29,365

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.88
  • Number of Estimates 7
  • High Estimate -0.77
  • Low Estimate -0.99
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -79.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.25 +4.80%
on 07/27/21
74.10 -28.93%
on 06/28/21
-20.84 (-28.35%)
since 06/25/21
3-Month
50.25 +4.80%
on 07/27/21
74.10 -28.93%
on 06/28/21
-7.73 (-12.80%)
since 04/27/21
52-Week
50.05 +5.21%
on 04/21/21
90.00 -41.49%
on 09/14/20
-24.52 (-31.77%)
since 07/27/20

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com...

AXSM : 52.66 (+1.68%)
Axsome Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

AXSM : 52.66 (+1.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

NEW YORK, NY / ACCESSWIRE / July 21, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are advised...

AXSM : 52.66 (+1.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ:AXSM). Such investors are advised...

AXSM : 52.66 (+1.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are advised to contact at   or...

AXSM : 52.66 (+1.68%)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Axsome Therapeutics, Inc. (AXSM) Investigation

NEW YORK, NY / ACCESSWIRE / July 15, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Axsome Therapeutics, Inc. ('Axsome" or 'the Company') (NASDAQ:AXSM)....

AXSM : 52.66 (+1.68%)
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag

The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.

PFE : 42.10 (+0.69%)
JAZZ : 173.71 (+0.26%)
AXSM : 52.66 (+1.68%)
HRMY : 25.68 (-3.89%)
Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021

Axsome to host conference call and webcast on Monday, August 9, 2021 at 8:00 AM Eastern Time

AXSM : 52.66 (+1.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM).  Such investors are advised to contact at  ...

AXSM : 52.66 (+1.68%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 119.81 (+0.24%)
ACRX : 1.1900 (-1.65%)
ACOR : 3.96 (-7.69%)
AXSM : 52.66 (+1.68%)
BAYRY : 14.9200 (-1.33%)
BDRFF : 119.7000 (unch)
BDSI : 3.64 (+0.55%)
BMY : 67.49 (-0.30%)
COLL : 24.76 (+0.61%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3600 (-1.45%)
EGLT : 0.0315 (-63.37%)
LLY : 243.58 (+0.15%)
FLXN : 6.14 (-1.13%)
GLPG : 60.37 (+0.48%)
HRTX : 12.24 (-2.47%)
KMPH : 10.76 (+0.09%)
MRK : 77.85 (+0.79%)
MESO : 7.04 (-1.68%)
NKTR : 15.91 (-2.03%)
NVS : 91.32 (+0.40%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.10 (+0.69%)
REGN : 581.01 (+0.56%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

3rd Resistance Point 56.78
2nd Resistance Point 54.99
1st Resistance Point 53.83
Last Price 52.66
1st Support Level 50.87
2nd Support Level 49.08
3rd Support Level 47.92

See More

52-Week High 90.00
Fibonacci 61.8% 74.74
Fibonacci 50% 70.03
Fibonacci 38.2% 65.31
Last Price 52.66
52-Week Low 50.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar